Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (449)	10/2/1998 6:50:00 PM
From: James Perry	Read Replies (1) \| Respond to of 1025

I saw the post. I have no knowledge about visitors from Roche, however I would tend to believe it to be true simply because it is a natural sequallae to Sam's visit to Switzerland. I think a settlement is close. I do believe that if settlement gives Roche the right to avoid future royalties, it would be worth a high dollar/per/share price, and I sure can't argue with $40. Roche has the ability to pay they kind of money. But Roche undoubtedly wants to distribute the POC, also. I don't think $40 would also cover a waiver of royalties for that device, as well. Why would they want to buy out one device, if they had to keep paying for the other? Would Igen want to consider waiving future royalties on both, for cash now? I am not at all sure - that is a transfer of a substantial segment of the company, leaving only the big device market for high throughput. Could a settlement just cover past royalty payments, and provide a scheme to monitor payments in the future? I think so. If so, I am sure it would involve less money. That is not what BMG first said she wanted, when payments of royalties started running slow. But I am sure she did not dream just how big what she was trying to take would become. I have all these thoughts, but I always conclude with the fact that any settlement would be a real kick in the stock for Igen!